Jubilant Pharmo

Which are the latest news on Jubilant Pharmo?

Why is Jubilant Pharmova Ltd falling/rising?

As of N/A, Jubilant Pharmova Ltd's stock price has risen by 0.73% recently, but it has declined by -15.88% over the past year, significantly underperforming the market. The company faces ongoing profitability issues, with a -10.2% drop in profits and negative long-term growth trends.

As of N/A, Jubilant Pharmova Ltd's stock price is currently rising, with a change of 6.75, representing an increase of 0.73%. Despite this short-term rise, the stock has shown a significant decline over the longer term. Over the past year, it has generated a return of -15.88%, which is considerably worse than the market average, as the BSE500 has returned 4.11% during the same period. <BR><BR>The company's profits have also decreased, with a reported fall of -10.2% in profits over the past year. Additionally, the operating profit has declined at an annual rate of -8.03% over the last five years, indicating poor long-term growth prospects. The recent financial results show a decrease in profit before tax and profit after tax, with falls of -15.91% and -17.5%, respectively, for the latest quarter.<BR><BR>While the stock is trading at a discount compared to its peers and has high institutional holdings at 28.27%, which have increased by 0.75% over the previous quarter, these factors have not been sufficient to offset the negative trends in profitability and long-term growth. Therefore, while there is a slight rise in the stock price currently, the overall performance and outlook remain concerning.

Should I buy, sell or hold Jubilant Pharmova Ltd?

When is the next results date for Jubilant Pharmova Ltd?

The next results date for Jubilant Pharmova Ltd is August 10, 2026.

The next results date for Jubilant Pharmova Ltd is scheduled for August 10, 2026.

How big is Jubilant Pharmo?

As of 10th June, Jubilant Pharmova Ltd has a market capitalization of 15,375.00 Cr, with recent net sales of 8,279.60 Cr and a net profit of 398.50 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Jubilant Pharmova Ltd has a market capitalization of 15,375.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 8,279.60 Cr, while the sum of Net Profit for the same period is 398.50 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 6,254.90 Cr, and Total Assets are valued at 12,499.00 Cr.

Who are in the management team of Jubilant Pharmo?

The management team of Jubilant Pharma includes Chairman Shyam S Bhartia, Co-Chairman Hari S Bhartia, Managing Director Priyavrat Bhartia, and Joint Managing Director Arjun Shanker Bhartia, along with other key executives and several Non-Executive and Independent Directors. This diverse team contributes extensive experience and expertise to the company.

The management team of Jubilant Pharma includes the following key individuals:<BR><BR>1. **Shyam S Bhartia** - Chairman (Non-Executive)<BR>2. **Hari S Bhartia** - Co-Chairman & Non-Executive Director<BR>3. **Priyavrat Bhartia** - Managing Director<BR>4. **Arjun Shanker Bhartia** - Joint Managing Director<BR>5. **Arvind Chokhany** - Whole Time Director & CFO<BR>6. **R Kumar** - Whole Time Director<BR>7. **Naresh Kapoor** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several Non-Executive and Independent Directors, including:<BR><BR>- **S Sridhar**<BR>- **Sudha Pillai**<BR>- **Ashok Misra**<BR>- **Vivek Mehra**<BR>- **Sushil Kumar Roongta**<BR>- **Arun Seth**<BR>- **Shirish Gundopant Belapure**<BR><BR>This diverse team brings a wealth of experience and expertise to the company.

Who are the peers of the Jubilant Pharmo?

Jubilant Pharmo's peers include Granules India, ERIS Lifescience, Caplin Point Lab, and others, with varying management risks and growth rates. Granules India leads in 1-year returns at 45.79%, while Jubilant Pharmo has a return of -16.32%.

Peers: The peers of Jubilant Pharmo are Granules India, ERIS Lifescience, Caplin Point Lab, Cohance Life, Natco Pharma, Alembic Pharma, Concord Biotech, Alivus Life, Marksans Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Granules India, Caplin Point Lab, Natco Pharma, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma, while Good management risk is found at ERIS Lifescience. Average management risk is found at Cohance Life and Jubilant Pharmo, while Viyash Scientifi has a Below Average management risk. All peers exhibit Below Average growth, except for Granules India, Caplin Point Lab, and Natco Pharma, which have Excellent growth. Jubilant Pharmo has an Average capital structure, while Excellent capital structure is noted at Granules India, Caplin Point Lab, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma, with Good capital structure at ERIS Lifescience.<BR><BR>Return Snapshot: Granules India has the highest 1-year return at 45.79%, while Cohance Life has the lowest at -57.72%. Jubilant Pharmo's 1-year return of -16.32% is better than Cohance Life's but worse than Granules India's. Additionally, the six-month returns for ERIS Lifescience, Cohance Life, Natco Pharma, Alembic Pharma, and Concord Biotech are negative.

What does Jubilant Pharmo do?

Jubilant Pharmova Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹2,290 Cr and a net profit of ₹119 Cr for March 2026. It has a market cap of ₹15,375 Cr and key metrics include a P/E ratio of 35.00 and a dividend yield of 0.52%.

Overview:<BR>Jubilant Pharmova Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was initially incorporated as 'Vam Organic Chemicals Limited' in 1978. It underwent several name changes, becoming 'Jubilant Organosys Limited' in November 2001, 'Jubilant Life Sciences Limited' in October 2009, and finally 'Jubilant Pharmova Limited' in February 2021. The most recent quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 2,290 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 119 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 15,375 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.52% <BR>Debt Equity: 0.33 <BR>Return on Equity: 6.14% <BR>Price to Book: 2.17 <BR><BR>Contact Details:<BR>Address: Bhartiagram Gajraula, Amroha Uttar Pradesh: 244223 <BR>Tel: 91-5924-267200 <BR>Email: investors@jubl.com/support@jubl.com <BR>Website: http://www.jubilantpharmova.com

Are Jubilant Pharmova Ltd latest results good or bad?

Jubilant Pharmova Ltd's latest results show strong revenue growth of 18.73% year-on-year, reaching ₹2,290 crores, and a significant sequential net profit recovery of 113.60%. However, concerns arise from a 22.27% year-on-year decline in net profit and a decrease in operating margin, indicating potential challenges in cost management.

Jubilant Pharmova Ltd's latest results present a mixed picture. On one hand, the company achieved a significant revenue growth of 18.73% year-on-year, reaching ₹2,290 crores in Q4 FY26, which is commendable and indicates strong sales momentum. Additionally, the net profit saw a remarkable sequential recovery, jumping 113.60% from the previous quarter to ₹119.40 crores.<BR><BR>However, there are notable concerns regarding profitability. The net profit declined by 22.27% year-on-year, and the operating margin (excluding other income) decreased to 14.93%, down 310 basis points from the same quarter last year. This margin compression raises questions about the company's ability to manage costs effectively, particularly as employee costs surged by nearly 30% year-on-year, significantly outpacing revenue growth.<BR><BR>In summary, while Jubilant Pharmova's revenue growth is impressive, the decline in profitability and rising costs suggest underlying challenges that the company needs to address. Investors should be cautious, as the strong revenue figures may not fully reflect the company's operational health.

Is Jubilant Pharmo technically bullish or bearish?

As of December 3, 2025, Jubilant Pharma's technical trend has shifted to a bearish outlook, supported by mildly bearish MACD and KST indicators, alongside mixed signals from moving averages and Bollinger Bands.

As of 3 December 2025, the technical trend for Jubilant Pharmo has changed from mildly bullish to sideways. The current technical stance is bearish, with key indicators supporting this view. The MACD is mildly bearish on both the weekly and monthly time frames, and the KST also shows a mildly bearish trend. The Bollinger Bands indicate a bearish sentiment on the weekly chart, while the moving averages on the daily chart are mildly bullish, suggesting mixed signals. Overall, the weakness in the weekly indicators and the sideways trend suggest a bearish outlook with limited strength.

How has been the historical performance of Jubilant Pharmo?

Jubilant Pharmo's historical performance shows fluctuating financial metrics, with net sales increasing from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025, despite a peak of INR 9,110.82 crore in March 2019. The company has rebounded in profitability, with profit after tax rising to INR 836.80 crore in March 2025 from a loss of INR 77.13 crore in March 2023.

Answer:<BR>The historical performance of Jubilant Pharmo shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jubilant Pharmo's net sales have shown a steady increase from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025. However, this is a decline from the peak of INR 9,110.82 crore in March 2019. The total operating income followed a similar trend, reaching INR 7,234.50 crore in March 2025. The total expenditure, excluding depreciation, increased from INR 4,973.83 crore in March 2022 to INR 6,060.80 crore in March 2025. Operating profit (PBDIT) has fluctuated, peaking at INR 1,739.01 crore in March 2019 and dropping to INR 1,230.50 crore in March 2025. Profit before tax saw a significant recovery to INR 981.10 crore in March 2025, up from just INR 15.53 crore in March 2023. Profit after tax also rebounded to INR 836.80 crore in March 2025, compared to a loss of INR 77.13 crore in March 2023. The company's total assets increased from INR 9,829.60 crore in March 2022 to INR 12,499.00 crore in March 2025, while total liabilities rose from INR 9,829.60 crore to INR 12,499.00 crore in the same period. Cash flow from operating activities improved to INR 1,072.00 crore in March 2025, indicating a positive trend in cash generation. Overall, Jubilant Pharmo has demonstrated resilience with a recovery in profitability and growth in sales, despite facing challenges in previous years.

Is Jubilant Pharmo overvalued or undervalued?

As of November 3, 2025, Jubilant Pharma is fairly valued with a PE ratio of 37.37 and an EV to EBITDA of 14.49, positioned between peers like Sun Pharma and Cipla, despite facing challenges with an -8.16% return over the past year.

As of 3 November 2025, the valuation grade for Jubilant Pharmo has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 37.37, an EV to EBITDA of 14.49, and a PEG ratio of 1.35. In comparison to its peers, Sun Pharma has a PE ratio of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, indicating that Jubilant Pharmo is positioned in the middle range of its industry.<BR><BR>Despite recent stock performance showing a 4.09% gain over the past week compared to a -0.94% decline in the Sensex, the company's longer-term returns, particularly a -8.16% return over the past year, suggest some challenges ahead. Overall, the current valuation reflects a balance between growth expectations and market realities, placing Jubilant Pharmo in a fair valuation category amidst its peers.

Who are the top shareholders of the Jubilant Pharmo?

The top shareholders of Jubilant Pharma include Spb Trustee Company Pvt Ltd with 20.52%, 18 mutual fund schemes holding 3.66%, 151 foreign institutional investors at 17.22%, and East Bridge Capital Master Fund I Ltd as the largest public shareholder with 4.3%. Individual investors collectively own 17.75% of the shares.

The top shareholders of Jubilant Pharma include a mix of promoters and institutional investors. The majority shareholders are the promoters, with Spb Trustee Company Pvt Ltd holding the largest stake at 20.52%. <BR><BR>In terms of institutional holdings, 18 mutual fund schemes collectively hold 3.66% of the company, while 151 foreign institutional investors (FIIs) account for 17.22%. The highest public shareholder is East Bridge Capital Master Fund I Ltd, which holds 4.3%. Additionally, individual investors collectively own 17.75% of the shares.

Has Jubilant Pharmo declared dividend?

Yes, Jubilant Pharmova Ltd has declared a 500% dividend, amounting to ₹5 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over longer periods, despite some short-term fluctuations.

Jubilant Pharmova Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 5 per share<BR>- Ex-date: 02 Aug 2024<BR><BR>Dividend Yield: 0.44%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -5.83%, the dividend return was 0%, resulting in a total return of -5.83%.<BR><BR>For the 1 year period, the price return was 58.16%, the dividend return was 0.68%, leading to a total return of 58.84%.<BR><BR>Over the 2 years period, the price return was 235.09%, the dividend return was 2.44%, culminating in a total return of 237.53%.<BR><BR>In the 3 years period, the price return was 185.02%, the dividend return was 4.65%, which resulted in a total return of 189.67%.<BR><BR>During the 4 years period, the price return was 36.31%, the dividend return was 2.71%, giving a total return of 39.02%.<BR><BR>For the 5 years period, the price return was 98.97%, the dividend return was 2.94%, resulting in a total return of 101.91%.<BR><BR>Overall, Jubilant Pharmova Ltd has declared a significant dividend, and the total returns over various periods show a positive trend, particularly in the longer terms, indicating strong performance despite some short-term fluctuations.